CD274 and neoplasm: Results from the dose confirmation phase I first-in-human clinical trial testing the anti-LAG-3 antibody Favezelimab plus Pembrolizumab in previously treated patients with MSS mCRC showed that the dual blockade had a manageable safety profile and a promising antitumor activity, particularly in PD-L1 CPS ≥ 1 tumor.